These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47 related articles for article (PubMed ID: 21730077)
1. The 6-MP versus placebo clinical trial in acute leukemia. Gehan EA; Freireich EJ Clin Trials; 2011 Jun; 8(3):288-97. PubMed ID: 21730077 [TBL] [Abstract][Full Text] [Related]
2. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis. Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286 [TBL] [Abstract][Full Text] [Related]
3. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360 [TBL] [Abstract][Full Text] [Related]
4. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ; Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571 [TBL] [Abstract][Full Text] [Related]
5. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V; Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352 [TBL] [Abstract][Full Text] [Related]
6. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Colonna T; Korelitz BI Am J Gastroenterol; 1994 Mar; 89(3):362-6. PubMed ID: 8122645 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. Present DH; Korelitz BI; Wisch N; Glass JL; Sachar DB; Pasternack BS N Engl J Med; 1980 May; 302(18):981-7. PubMed ID: 6102739 [TBL] [Abstract][Full Text] [Related]
8. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729 [TBL] [Abstract][Full Text] [Related]
9. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Ribera JM; Ortega JJ; Oriol A; Fontanillas M; Hernández-Rivas JM; Brunet S; García-Conde J; Maldonado J; Zuazu J; Gardella S; Besalduch J; León P; Macià J; Domingo-Albós A; Feliu E; San Miguel JF Haematologica; 1998 Mar; 83(3):222-30. PubMed ID: 9573676 [TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816 [TBL] [Abstract][Full Text] [Related]
11. On plotting renovated samples. Smith PJ Biometrics; 1995 Sep; 51(3):1147-51. PubMed ID: 7548698 [TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306 [TBL] [Abstract][Full Text] [Related]
13. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068 [TBL] [Abstract][Full Text] [Related]
14. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922. Tolar J; Bostrom BC; La MK; Sather HN Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062 [TBL] [Abstract][Full Text] [Related]
15. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ; Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155 [TBL] [Abstract][Full Text] [Related]
16. How low is too low? Use of cluster analysis to define low levels of mercaptopurine metabolites. Traore F; O'Riordan MA; Myers C; Groth K; Hoff A; Angiolillo A; Rheingold S; Drotar D; Kodish E Pediatr Blood Cancer; 2006 Feb; 46(2):187-92. PubMed ID: 16086421 [TBL] [Abstract][Full Text] [Related]